Novartis expands Alcon campus in Texas; Glenmark shops for partners; Pfizer recants job cuts in Ireland;

@FiercePharma: ICYMI: This week's issue of FiercePharmaMarketing. Report | Follow @FiercePharma

@EricPFierce: Health Canada tells GSK to get its vaccine house in order as flu season approaches. More | Follow @EricPFierce

@CarlyHFierce: M&A spotlight: Allergan plots cost cuts to ward off Valeant, AbbVie may have to raise Shire bid--again. Story | Follow @CarlyHFierce

> Novartis ($NVS) says it will spend $35 million to build a new data center in Fort Worth, TX, for its Alcon unit, but will not be adding any jobs as a result. Story

> India's Glenmark Pharmaceuticals is in talks with foreign companies for a partnership on two of its biological drugs being tested for the treatment of chronic pain and autoimmune disorders. Story

> Number crunching by The Telegraph says that a combined AbbVie ($ABBV) and Shire ($SHPG) would have 30,300 employees and $23.7 billion in revenue, which would make it the top 10 of Big Pharma. Graph

> The International Council of Biotechnology Associations (ICBA) has been formed to advocate for public policy on global drug development. Report

Medical Device News

@FierceMedDev: We're looking for the fiercest companies in med tech for our 2014 Fierce 15 awards. More details here | Follow @FierceMedDev

@StacyALawrence: Zimmer, Biomet hit regulatory speedbump in pending merger. Story | Follow @StacyALawrence

@VarunSaxena2: JAMA study adds to robotic surgery safety concerns. Article | Follow @VarunSaxena2

@MichaelGFierce: MIT, MicroCHIPS develop remote-controlled contraceptive with on-off delivery. FierceDrugDelivery story | Follow @MichaelGFierce

@EmilyWFierce: laid out its new strategic plan for developing therapies for rare childhood diseases. PMLiVE article | Follow @EmilyWFierce

> USGI Medical fills enrollment for pivotal U.S. study of its incisionless, endoscopic weight loss procedure. Story

> FDA clears oral sleep apnea device as search for alternatives to CPAP therapy continues. Report

> Gynesonics aims for $35M for minimally invasive uterine fibroid device. Article

Biotech News

@FierceBiotech: Wall Street wonders what Shire is worth. Report | Follow @FierceBiotech

@JohnCFierce: Merck vet steps in to lead Third Rock's immuno-oncology upstart. Item | Follow @JohnCFierce

@DamianFierce: and DMD docs are upbeat on 144-week eteplirsen data, but shares are down about 10%. Article | Follow @DamianFierce

@EmilyMFierce: Faculty calls for removal of Scripps' leader amid USC merger talks. FierceBiotech Research story | Follow @EmilyMFierce

> Industry Voices: The contributions of immunology translational medicine to clinical pharmaceutical development. Report

> Regado slips again as FDA weighs in on halted cardio trial. News

> Regeneron, Sanofi herald a blockbuster contender with groundbreaking study. Article

> Bristol-Myers races to the FDA with immuno-oncology star nivolumab. Story

Vaccines News

> U.S. bioterror readiness highlighted after NIH smallpox discovery. Article

> Could soaring vaccine prices spark Sovaldi-style payer pushback? Story

> No link between Merck's Gardasil and blood clots, study says. Item

> Report: Manufacturing, logistical challenges to weigh down cancer vaccine market through 2022. More

> Canada gives GSK 30-day deadline for turnaround plans at FluLaval plant. Article

Pharma Manufacturing News

> Report: Dendreon's costly manufacturing casts doubt on cancer vax viability. Article

> Portfolio trimming by generics manufacturers linked to soaring drug costs. Item

> Global CMOs tipped to enter Russia as local drug production deadline nears. Story

> Serum Institute allies with biotech in bid to cut cost of biosimilar production. More

> India faces higher QC costs as Shasun shows value of compliance. Article

> U.K. commits cash to $24.7M industry-focused formulation center. Story

And Finally... Labor negotiations have saved 60 jobs at a Pfizer ($PFE) plant in Cork, Ireland. Story

Suggested Articles

The FDA has granted Amarin's Vascepa a possible blockbuster label expansion for CV risk reduction in patients with or without CV disease.

In a high-stakes patent lawsuit between CAR-T companies Bristol-Myers Squibb and Gilead Sciences, BMS has come up with a victory. 

It’s been a year of ups and downs for Pfizer’s Xeljanz. But the company is hoping to close on a high note, with help from a new extended-release pill.